Times Literary Supplement (May 12, 2023) – This week’s @TheTLS, features Peter Thonemann on The Triumph of the West; @joemoransblog on imagination; @michaelscaines on The Motive and the Cue; @DrAliceKelly on graphic novelizations of Gatsby; @helenlpgordon on stones; @rinireg on surveillance – and more.
In London, I had taken A Young Woman Standing at a Virginal for a dependable rest point on strolls around the National Gallery. In Amsterdam, relocated to join 27 other Vermeers in the Rijksmuseum exhibition, its strangeness re-emerged. This canvas, executed towards the end of Vermeer’s relatively brief career (some four years, perhaps, before he died aged 43 in 1675), commits to a tactic he had earlier only toyed with: to set an internal picture as a wholly self-contained block within his own composition, uninterrupted by foreground forms.
Collaborating on his memoir, “Spare,” meant spending hours together on Zoom, meeting his inner circle, and gaining a new perspective on the tabloids.
For more than a decade, two “recovering” anthropologists have brought documentary closer to the human experience. Now they’ve made the camera part of our flesh and blood.
In Johann Eckermann, Goethe found an amanuensis made in heaven.
Conversations with Goethe: In the Last Years of His Life by Johann Peter Eckermann, translated from the German by Allan Blunden, with an introduction and notes by Ritchie Robertson
A strange time to publish—strange time to publish anything—a translation of Eckermann’s Conversations with Goethe (or should that be Goethe’s Conversations with Eckermann?), in six hundred static, major-key pages that can easily feel like twice as many. The big man, himself by now somewhat fallen on hard times, recorded by the little acolyte.
A new book reveals the split personality of the biotech industry: an altruistic enterprise that creates breakthrough treatments for patients in need, and a bare-knuckle business that seeks to generate astronomic profits and stop competitors from developing better treatments.
For Blood and Money: Billionaires, Biotech, and the Quest for a Blockbuster Drug by Nathan Vardi
A research scientist for Pharmacyclics, Sunnyvale, California, 2013. In For Blood and Money, Nathan Vardi writes that when Pharmacyclics—which developed ibrutinib, a treatment for chronic lymphocytic leukemia—was bought by the pharmaceutical giant AbbVie in 2015 for $21 billion, ‘the deal…set the new high-water mark for success in the biotechnology industry.’
Times Literary Supplement @TheTLS (May 5, 2023) – This week’s @TheTLS features Bruno Schulz – a writer from another Europe; Patrick O’Brian’s bleak vision; Vermeer – a great but flawed exhibition; extreme fandom and Derek Parfit, eccentric genius.
It’s more than a little discomfiting to read the great Polish novelist Witold Gombrowicz’s description, in his diary from the early 1960s, of his not-quite-friend Bruno Schulz: “A tiny gnome with enormous head, appearing too scared to dare exist, he was rejected by life and slouched along its peripheries”. Written for publication two decades after Schulz was gunned down by a Nazi just outside the ghetto of his occupied native town of Drohobych in November 1942, these words cannot help but seem impious.
Literary Review – May 2023 issue: Donald Rayfield surveys the life and work of the Russian poet Osip Mandelstam and R W Johnson reviews the Mandela’s…
‘Osip Mandelstam: A Biography’ By Ralph Dutli
When in 1960 I first came across Osip Mandelstam’s poetry, nobody in the USSR had enjoyed access to his work since the early 1930s and few even knew of his existence, let alone of his death, as he had predicted, in Stalin’s Gulag. His books had been removed from libraries and bookshops.
‘Winnie and Nelson: Portrait of a Marriage’ By Jonny Steinberg
Under apartheid, aspiring South African writers frequently marketed themselves to the world as committed and heroic anti-apartheid activists. The enormous success of Alan Paton’s Cry, the Beloved Country (fifteen million copies sold and counting) showed the way, though Paton was the real McCoy, a committed liberal who suffered for his beliefs.
As Prince of Wales, Charles was always ready with an opinion. Now, with his coronation at hand, his job is to have none.
“My great problem in life is that I do not really know what my role in life is,” Charles once said, adding, “I must find one.”Photo illustration by Alma Haser for The New Yorker; Source photographs from Getty
The artist discusses being young and adrift in London, and gives King Charles tips for painting with watercolors.
New Yorker covers don’t always reflect current events, but some staged proceedings, both anachronistic and immemorial, can be catnip for cartoonists and commentators alike. King Charles III automatically acceded to the throne when his mother, Queen Elizabeth II, died on September 8, 2022. Charles, the longest-serving heir apparent in Britain’s history, spent seven decades preparing for the role of monarch. He became the next in line to reign over the United Kingdom at three years old, when Elizabeth became queen, in 1952.
Times Literary Supplement @TheTLS (April 28, 2023) – This week’s @TheTLS, featuring Abigail Green on 1848; @WeTheBrandon on the geopolitics of space; @woodsgregory on James Purdy; @JulianBaggini on food policy; @scheffer_pablo on the Passion in the Netherlands; @CamilleRalphs_ on poetry anthologies – and more
Pensions – and ‘the fiscal impact of ageing’ – have long troubled the EU. A European Commission paper published in 2016 noted with relief that ‘most EU member states’ were reforming their pension systems. France is one of them. During his first term in office Emmanuel Macron envisaged an ambitious reform plan, but Covid-19 put paid to it. Re-elected in 2022, he put a different plan on the table; at its core is an increase in the retirement age from 62 to 64. It has been predictably unpopular. Pensions rank high on the list of French state expenditures. They are one of the cornerstones in France’s edifice of public provision, which is why the sound of drilling and hammering sets most citizens’ teeth on edge.
Boomers Daily 